MedTrace Logo

A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

NCT02670746 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2019-09-16

No results posted yet for this study

Summary

The objective of the study is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma in the Netherlands. Additional objectives are to monitor the incidence and reversibility of neuropathy during treatment, to assess the patient's Quality of life when treated with nab-paclitaxel/gemcitabine and to evaluate the use of resources that come with treating metastatic pancreatic cancer.

Conditions

  • Pancreatic Neoplasms

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Jeroen Stevens, Msc · Celgene Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2017-11-28
Completion
2017-11-28

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02670746 on ClinicalTrials.gov